stockrow
Saturday 7 November 2026
Export ZURA’s income statement to Excel — free account
Zura Bio Limited
ZURA Healthcare Biotechnology
- EPS
- +3.71%
- Free cash flow
- −26.2%
Quarter to September 2026, against a year earlier
4.11
0.39
+10.48%
Follow ZURA
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
11.29 | 12.90 | 19.33 | 9.05 |
+8 more quarters Free account |
Net Debt/EBITDA |
6.53 | 7.00 | 8.85 | 5.95 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.76 | 0.79 | 0.78 | 0.49 | |
Capex/Depreciation |
(1.80) | (1.50) | (0.81) | (1.13) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.15) | (0.16) | (0.17) | (0.24) | |
Cash per Share |
1.47 | 1.62 | 2.01 | 1.16 | |
Shareholders Equity per Share |
1.39 | 1.55 | 1.93 | 1.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.39 | 1.55 | 1.93 | 1.08 | |
Free Cash Flow |
(19.53) | (20.92) | (18.94) | (22.29) | |
Working Capital |
174.62 | 194.18 | 215.26 | 99.90 | |
Capital Expenditures |
(0.04) | (0.02) | (0.01) | (0.02) | |
Net Current Asset Value |
174.62 | 194.18 | 215.26 | 99.90 | |
| Other line items | |||||
Quick Ratio |
11.06 | 12.57 | 19.21 | 8.82 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.15) | (0.16) | (0.17) | (0.24) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
21.23 | 17.51 | 16.42 | 15.96 | |
Average Assets |
169.28 | 185.60 | 200.57 | 146.74 | |
Average Common Equity |
143.72 | 162.27 | 178.32 | 124.95 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026